With the increasing understanding of epilepsy's pathophysiology and the development of new diagnostic and treatment modalities, the management of epilepsy has significantly evolved. This article aims to provide an update on the latest advancements in epilepsy management.
Modern diagnostic tools, such as 3D-MRI and PET scans, have improved the detection and localization of epileptogenic foci. High-density EEG, which allows for more precise spatial sampling, has also become more prevalent. These advancements have boosted the accuracy of epilepsy diagnosis and assessment.
There has been a surge in the development of new antiepileptic drugs (AEDs) with better efficacy and fewer side effects. Drugs like cenobamate and fenfluramine have shown promising results in controlling seizures. In addition, the resurgence of dietary therapies, such as the ketogenic diet, has provided alternative treatment options for drug-resistant epilepsy.
Surgical management of epilepsy has also seen significant advancements. Minimally invasive surgical techniques, such as stereotactic laser ablation and neuromodulation devices, have improved patient outcomes. These techniques offer less postoperative morbidity and a quicker recovery time compared to traditional resective surgery.
Telemedicine has emerged as a powerful tool in epilepsy management, particularly during the COVID-19 pandemic. It has proven effective in delivering care, managing treatment plans, and monitoring seizure control remotely, thus overcoming geographical barriers and improving access to specialist care.
In conclusion, the field of epilepsy management has seen significant advancements in recent years. These developments promise a more accurate diagnosis, effective treatment, and improved quality of life for patients with epilepsy. As healthcare professionals, it is crucial to stay updated with these advancements to provide the best possible care to our patients.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation